Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing investigational therapies for chronic cough. Its lead product candidate is Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is being studied in a phase 2b clinical trial called Cough Reduction in IPF with nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease. Additionally, the company is conducting a phase 2a clinical trial for refractory chronic cough. Trevi Therapeutics has a license agreement with Keenova Therapeutics plc for the development and commercialization of products incorporating nalbuphine hydrochloride in various formulations.

Trevi Therapeutics, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol TRVI. The company's shares are traded in United States Dollars (USD), which is the official currency of the United States. As a Nasdaq-listed company, it operates under the regulatory framework of the U.S. Securities and Exchange Commission (SEC) and follows standard reporting and compliance requirements for publicly traded companies in the United States.

Trevi Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing therapies for conditions with high unmet medical needs, such as chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough. The biotechnology industry involves using biological processes and living organisms to develop drugs and treatments, and Trevi's work with nalbuphine-based therapies places it squarely in this innovative field.

Trevi Therapeutics, Inc. is headquartered in New Haven, Connecticut, United States. The company was incorporated in 2011, making it a relatively young biopharmaceutical firm. Its operations are primarily focused on the United States, as indicated by its country and region designation. The company's research and development activities are centered around its lead candidate Haduvio, and it collaborates with Keenova Therapeutics plc through a license agreement to develop and commercialize nalbuphine hydrochloride formulations.

As a clinical-stage biopharmaceutical company, Trevi Therapeutics does not yet have any approved products or commercial sales. Its business model revolves around the research and development of investigational therapies, particularly Haduvio (nalbuphine ER) for chronic cough in IPF and refractory chronic cough. The company generates revenue primarily through licensing agreements, such as its license agreement with Keenova Therapeutics plc, which grants rights to develop and commercialize products incorporating nalbuphine hydrochloride. Future revenue is expected to come from potential product sales if Haduvio or other candidates receive regulatory approval and are successfully commercialized.